Patents Intangible: Legal Right Booked as an Asset

Key Takeaways

• Patents are finite-lived intangibles amortized over the shorter of legal life (up to 20 years) or estimated economic life.
• Acquired patents are recorded at fair value under ASC 805 and amortized under ASC 350-30.
• Internally generated patents capture only legal and filing costs, not the underlying R&D expense.
• Patent cliffs in pharma can produce sharp drops in operating income as amortization ends alongside revenue.

What It Is

A patent is a government granted exclusive right to make, use, or sell an invention, typically for 20 years from the filing date in the United States. On the balance sheet, a patent is an intangible asset, almost always finite lived, and amortized through the income statement.

Patents appear inside intangible assets, with the gross amount, accumulated amortization, and remaining weighted average life disclosed in a footnote. When the gross balance exceeds five percent of total assets, SEC registrants must disclose patents separately under Regulation S-X Rule 5-02.

The Intuition

Patents have a hard legal expiration date, which makes the accounting cleaner than for most intangibles. The economic logic mirrors the legal logic: you paid for an exclusive right with a known end, and you write it off over the period in which it can produce value.

Investors look at patents for two signals. First, the size of the balance hints at R&D heritage and acquisition activity. Second, the amortization roll-off schedule, often disclosed by year, gives a multi-year preview of expense changes. Pharma's "patent cliff" is the most dramatic example.

How It Works

Under ASC 805, patents acquired in a business combination are recognized at fair value. Patents bought separately, such as in a license-and-purchase deal, are recorded at cost. For internally developed patents, ASC 730 requires that R&D be expensed as incurred. Only direct legal, filing, and registration costs may be capitalized.

ASC 350-30 requires amortization over the asset's useful life, defined as the shorter of:

• The asset's contractual or legal life, capped at 20 years for US utility patents
• The economic life, considering competitive substitutes and obsolescence

Annual amortization = (gross cost - residual value) / useful life

Amortization should reflect the pattern in which economic benefits are consumed. Straight-line is the default when the pattern cannot be reliably determined. The asset is tested for impairment under ASC 360 when a triggering event suggests carrying value exceeds recoverable cash flows.

When a patent expires, the carrying value should already be fully amortized. Any unamortized balance, perhaps after an unfavorable legal ruling, is written off.

Worked Example

A medical device company acquires a smaller competitor for $1.2 billion. Purchase price allocation assigns $300 million to patents, $150 million to developed technology, $100 million to customer relationships, and $650 million to goodwill.

The acquired patent portfolio has a weighted average remaining legal life of 12 years, but management estimates an economic life of 8 years due to expected competing devices. Amortization is set at 8 years, straight-line, producing $37.5 million of annual expense.

Six years in, a generic-equivalent device clears regulatory approval. Sales of products covered by the patents drop sharply. Management tests the remaining $75 million carrying value, concludes recoverable cash flows are $30 million, and books a $45 million impairment, accelerating what would have otherwise been two more years of amortization.

Common Mistakes

1. Confusing legal life with useful life. Patents can be amortized over a shorter economic life if obsolescence is foreseeable. Always read the footnote disclosure.
2. Capitalizing internal R&D as patents. Only legal and filing costs may be capitalized for self-developed patents. The underlying research is expensed under ASC 730.
3. Ignoring patent cliffs. Pharma firms disclose expiration schedules. Failure to model the related amortization and revenue rollover overstates future earnings.
4. Treating patent amortization as cash cost. Cash was spent at acquisition or filing. Amortization is allocation, so many investors add it back when assessing cash-based returns.
5. Mixing patents with other intangibles. Patents, trademarks, customer relationships, and developed technology each have distinct economic lives. Aggregate amortization disclosure can hide that.

Frequently Asked Questions

What is a patents intangible in simple terms? It is the recorded value of patents a company owns, shown as an intangible asset on the balance sheet. The cost is amortized through the income statement over the patent's useful life.

How does the patents intangible affect investment decisions? A large patents balance suggests an R&D heavy or acquisition heavy company. The amortization schedule signals future expense changes that investors use to project margins.

What is a real-world example of a patents intangible? A pharmaceutical company that acquires a drug developer often books hundreds of millions in patents tied to specific compounds. As those patents near expiration, amortization tapers and revenue typically falls.

How can investors avoid being misled by patents amortization? Read the intangible footnote for useful life and remaining amortization schedule, and stress test what happens at patent cliff dates.

How is the patents intangible different from developed technology? Patents are specific legal rights with a defined legal life. Developed technology is the broader know-how and working product, often amortized over a different period and with weaker legal protection.

Sources

1. Deloitte DART. 4.3 Intangible Assets Subject to Amortization (ASC 350-30). https://dart.deloitte.com/USDART/home/codification/assets/asc350-20/goodwill/chapter-4-subsequent-accounting-for-intangible/4-3-intangible-assets-subject-amortization
2. PwC Viewpoint. 4.3 Types of Identifiable Intangible Assets in Business Combinations. https://viewpoint.pwc.com/dt/us/en/pwc/accounting_guides/business_combination/business_combination__28_US/chapter_4_intangible_US/43_types_of_identifi_US.html
3. Deloitte DART. 5.3 Intangible Asset Presentation and Disclosure Requirements. https://dart.deloitte.com/USDART/home/codification/assets/asc350-20/goodwill/chapter-5-presentation-disclosure-requirements/5-3-presentation-disclosure-requirements-for
4. Accounting Insights. Understanding ASC 350-30 Accounting for Intangible Assets. https://accountinginsights.org/understanding-asc-350-30-accounting-for-intangible-assets/

Disclaimer

This article is educational content only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed advisor before making investment decisions.